Postoperative Diagnosis and Treatment of One Case of Thyroid Cancer：a Biopsychosocial Perspective

doi:10.12114/j.issn.1007-9572.2020.00.014

Abstract

Abstract: The patient-centered medical home （PCMH） is an optimized model used for delivering general care from biological，psychological and social perspectives by the healthcare team consisting of professionals in various fields.How to appropriately use this kind of biopsychosocial approach to treat patients is a great challenge to general practitioners （GPs）.We reported a 31-year-old female patient who was admitted to the PCMH，Beijing Jiaotong University Community Health Center on December 7，2018，and was given treatment using a biopsychosocial approach.This case mainly complained of 13-year irregular menstruation，six months after thyroid cancer surgery，and requiring comprehensive treatment.Moreover，she was found with polycystic ovary syndrome，type 2 diabetes，temperaments of pursuing perfection and high self-esteem，and fertility needs.Instead of treating patients by some specialists only from the biological perspective，GPs should systematically and comprehensively analyze the patients' complex conditions，and recognize that the patient needed biological treatment，psychological counseling，and support from her family and work unit，and then develop treatment regimen using a biopsychosocial approach.

Key words: Thyroid neoplasms, Polycystic ovary syndrome, General practice, Bio-psycho-social

摘要： 以患者为中心的医疗之家，通过健康团队的形式将各领域的专业人员集中在一起，整合生物、心理、社会的各方面来评估治疗患者，这是非常优化的全科医学模式，同时也对全科医生提出了巨大挑战。本文报道1例31岁女性患者，以“月经不规律13年，甲状腺癌术后6个月，想了解如何全面治疗”为主诉于2018-12-07就诊于北京交通大学社区卫生服务中心医疗之家，本例患者甲状腺癌术后，同时患有多囊卵巢综合征、2型糖尿病，性格上追求完美，自我要求高，有生育需求。从这个真实的患者身上，能看到全科医生的重要性。患者不仅需要生物层面对症治疗，还需要心理疏导，同时协调家庭、单位的资源。这是全科医生与专科医生的最大区别，全科医生以系统观看待患者，层层剖析复杂的病情，基于生物-心理-社会医学模式提出治疗方案。

关键词: 甲状腺肿瘤, 多囊卵巢综合征, 全科医学, 生物-心理-社会

XIE Xingwei,LIU Chunmei,LIU Shuxian, et al. Postoperative Diagnosis and Treatment of One Case of Thyroid Cancer：a Biopsychosocial Perspective　[J]. Chinese General Practice, 2020, 23(5): 623-628. DOI: 10.12114/j.issn.1007-9572.2020.00.014.
谢兴伟,刘春梅,刘书仙等. 基于“生物-心理-社会”模式的甲状腺癌术后患者一例报道及全科诊疗思路[J]. 中国全科医学, 2020, 23(5): 623-628. DOI: 10.12114/j.issn.1007-9572.2020.00.014.

References

［1］RAKEL R E，RAKEL D P.全科医学［M］．曾益新，译.北京：人民卫生出版社，2012：25-26.
［2］高明.甲状腺结节和分化型甲状腺癌诊治指南［J］．中国肿瘤临床，2012，39（17）：1249-1272．DOI：10.3969/j.issn.1000-8179.2012.17.003.http：//www.cnki.com.cn/Article/CJFDTotal-ZGZL201217004.htm.
［3］HAUGEN B R，ALEXANDER E K，BIBLE K C，et al．2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer：the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer［J］．Thyroid，2016，26（1）：1-133．DOI：10.1089/thy.2015.0020.
［4］GUIMARAES V，DEGROOT L J.Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing［J］．Thyroid，1996，6（2）：69-73．DOI：10.1089/thy.1996.6.69.
［5］COBIN R H，GHARIB H，BERGMAN D A，et al．AACE/AAES medical/surgical guidelines for clinical practice：management of thyroid carcinoma.American Association of Clinical Endocrinologists.American College of Endocrinology［J］．Endocr Pract，2001，7（3）：202-220.
［6］British Thyroid Association，Royal College of Physicians.Guidelines for the management of thyroid cancer，2007［EB/OL］．（2012-10-10）［2019-08-15］．http：//www.british-thyroid-association.org/news/Docs/Thyroid_cancer_guidelines_2007.pdf.
［7］MCLEOD D S，SAWKA A M，COOPER D S.Controversies in primary treatment of low-risk papillary thyroid cancer［J］．Lancet，2013，381（9871）：1046-1057．DOI：10.1016/S0140-6736（12）62205-3.
［8］MAZZAFERRI E L，ROBBINS R J，SPENCER C A，et al．A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma［J］．J Clin Endocrinol Metab，2003，88（4）：1433-1441．DOI：10.1210/jc.2002-021702.
［9］SHAHA A R，LOREE T R，SHAH J P.Prognostic factors and risk group analysis in follicular carcinoma of the thyroid［J］．Surgery，1995，118（6）：1131-1138．DOI：10.1016/s0039-6060（05）80124-2.
［10］KNOCHENHAUER E S，KEY T J，KAHSAR-MILLER M，et al．
Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States：a prospective study［J］．J Clin Endocrinol Metab，1998，83（9）：3078-3082．DOI：10.1210/jcem.83.9.5090.
［11］DIAMANTI-KANDARAKIS E，KOULI C R，BERGIELE A T，et al．A survey of the polycystic ovary syndrome in the Greek island of Lesbos：hormonal and metabolic profile［J］．J Clin Endocrinol Metab，1999，84（11）：4006-4011．DOI：10.1210/jcem.84.11.6148.
［12］ASUNCIóN M，CALVO R M，SAN MILLáN J L，et al．A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain［J］．J Clin Endocrinol Metab，2000，85（7）：2434-2438．DOI：10.1210/jcem.85.7.6682.
［13］LIM S S，HUTCHISON S K，VAN RYSWYK E，et al．Lifestyle changes in women with polycystic ovary syndrome［J］．Cochrane Database Syst Rev，2019，3：CD007506．DOI：10.1002/14651858.CD007506.pub4.
［14］GIBSON-HELM M，TEEDE H，DUNAIF A，et al．Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome［J］．J Clin Endocrinol Metab，2017，102（2）：604-612．DOI：10.1210/jc.2016-2963.
［15］PASQUALI R，ANTENUCCI D，CASIMIRRI F，et al．Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss［J］．J Clin Endocrinol Metab，1989，68（1）：173-179．DOI：10.1210/jcem-68-1-173.
［16］KIDDY D S，HAMILTON-FAIRLEY D，BUSH A，et al．Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome［J］．Clin Endocrinol （Oxf），1992，36（1）：105-111．DOI：10.1111/j.1365-2265.1992.tb02909.x.
［17］HUBER-BUCHHOLZ M M，CAREY D G，NORMAN R J.Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome：role of insulin sensitivity and luteinizing hormone［J］．J Clin Endocrinol Metab，1999，84（4）：1470-1474．DOI：10.1210/jcem.84.4.5596.
［18］CROSIGNANI P G，COLOMBO M，VEGETTI W，et al．Overweight and obese anovulatory patients with polycystic ovaries：parallel improvements in anthropometric indices，ovarian physiology and fertility rate induced by diet［J］．Hum Reprod，2003，18（9）：1928-1932．DOI：10.1093/humrep/deg367.
［19］American Diabetes Association，BANTLE J P，WYLIE-ROSETT J，et al．Nutrition recommendations and interventions for diabetes：a position statement of the American Diabetes Association［J］．Diabetes Care，2008，31（Suppl 1）：S61-78．DOI：10.2337/dc08-S061.
［20］BRAND-MILLER J，HAYNE S，PETOCZ P，et al．Low-glycemic index diets in the management of diabetes：a meta-analysis of randomized controlled trials［J］．Diabetes Care，2003，26（8）：2261-2267．DOI：10.2337/diacare.26.8.2261.
［21］THOMAS D，ELLIOTT E J.Low glycaemic index，or low glycaemic load，diets for diabetes mellitus［J］．Cochrane Database Syst Rev，2009（1）：CD006296．DOI：10.1002/14651858.CD006296.pub2.
［22］HARRISON C L，LOMBARD C B，MORAN L J，et al．Exercise therapy in polycystic ovary syndrome：a systematic review［J］．Hum Reprod Update，2011，17（2）：171-183．DOI：10.1093/humupd/dmq045.
［23］MARSON J W，BALDWIN H E.An overview of acne therapy，part 2：hormonal therapy and isotretinoin［J］．Dermatol Clin，2019，37（2）：195-203．DOI：10.1016/j.det.2018.12.002.
［24］RANDEVA H S，TAN B K，WEICKERT M O，et al．Cardiometabolic aspects of the polycystic ovary syndrome［J］．Endocr Rev，2012，33（5）：812-841．DOI：10.1210/er.2012-1003.
［25］EHRMANN D A，SCHNEIDER D J，SOBEL B E，et al．Troglitazone improves defects in insulin action，insulin secretion，ovarian steroidogenesis，and fibrinolysis in women with polycystic ovary syndrome［J］．J Clin Endocrinol Metab，1997，82（7）：2108-2116．DOI：10.1210/jcem.82.7.4069.
［26］NESTLER J E，JAKUBOWICZ D J，REAMER P，et al．Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome［J］．N Engl J Med，1999，340（17）：1314-1320．DOI：10.1056/NEJM199904293401703.
［27］SEPILIAN V，NAGAMANI M.Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance［J］．J Clin Endocrinol Metab，2005，90（1）：60-65．DOI：10.1210/jc.2004-1376.
［28］MOGHETTI P，CASTELLO R，NEGRI C，et al．Metformin effects on clinical features，endocrine and metabolic profiles，and insulin sensitivity in polycystic ovary syndrome：a randomized，double-blind，placebo-controlled 6-month trial，followed by open，long-term clinical evaluation［J］．J Clin Endocrinol Metab，2000，85（1）：139-146．DOI：10.1210/jcem.85.1.6293.
［29］UNLüHIZARCI K，KELESTIMUR F，BAYRAM F，et al．The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome［J］．Clin Endocrinol （Oxf），1999，51（2）：231-236．DOI：10.1046/j.1365-2265.1999.00786.x.
［30］PASQUALI R，GAMBINERI A，BISCOTTI D，et al．Effect of long-term treatment with metformin added to hypocaloric diet on body composition，fat distribution，and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome［J］．J Clin Endocrinol Metab，2000，85（8）：2767-2774．DOI：10.1210/jcem.85.8.6738.
［31］YKI-J?RVINEN H，NIKKIL? K，M?KIMATTILA S.Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus［J］．Drugs，1999，58（Suppl 1）：53-54；discussion 75-82．DOI：10.2165/00003495-199958001-00012.
［32］STUMVOLL M，NURJHAN N，PERRIELLO G，et al．Metabolic effects of metformin in non-insulin-dependent diabetes mellitus［J］．N Engl J Med，1995，333（9）：550-554．DOI：10.1056/nejm199508313330903.
［33］Thessaloniki Eshre/Asrm-Sponsored Pcos Consensus Workshop Group.Consensus on infertility treatment related to polycystic ovary syndrome［J］．Fertil Steril，2008，89（3）：505-522．DOI：10.1016/j.fertnstert.2007.09.041.
［34］NIAFAR M，HAI F，PORHOMAYON J，et al．The role of metformin on vitamin B12 deficiency：a meta-analysis review［J］．Intern Emerg Med，2015，10（1）：93-102．DOI：10.1007/s11739-014-1157-5.
［35］ALEXANDER E K，PEARCE E N，BRENT G A，et al．2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum［J］．Thyroid，2017，27（3）：315-389．DOI：10.1089/thy.2016.0457.
［36］GLUECK C J，WANG P.Metformin before and during pregnancy and lactation in polycystic ovary syndrome［J］．Expert Opin Drug Saf，2007，6（2）：191-198．DOI：10.1517/14740338.6.2.191.
［37］CARMINA E，LOBO R A.Does metformin induce ovulation in normoandrogenic anovulatory women?［J］．Am J Obstet Gynecol，2004，191（5）：1580-1584．DOI：10.1016/j.ajog.2004.05.030.
［38］STUMVOLL M，NURJHAN N，PERRIELLO G，et al．Metabolic effects of metformin in non-insulin-dependent diabetes mellitus［J］．N Engl J Med，1995，333（9）：550-554．DOI：10.1056/NEJM199508313330903.
［39］GREENWOOD E A，PASCH L A，CEDARS M I，et al．Association among depression，symptom experience，and quality of life in polycystic ovary syndrome［J］．Am J Obstet Gynecol，2018，219（3）：279.e1-279.e7．DOI：10.1016/j.ajog.2018.06.017.
［40］BERNI T R，MORGAN C L，BERNI E R，et al．Polycystic ovary syndrome is associated with adverse mental health and neurodevelopmental outcomes［J］．J Clin Endocrinol Metab，2018，103（6）：2116-2125．DOI：10.1210/jc.2017-02667.
［41］SALVATORI M，PEROTTI G，RUFINI V，et al．Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?［J］．Clin Endocrinol （Oxf），2004，61（6）：704-710．DOI：10.1111/j.1365-2265.2004.02153.x.
［42］CHEN L B，LUO Q Y，SHEN Y，et al．Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma［J］．J Nucl Med，2008，49（12）：1952-1957．DOI：10.2967/jnumed.108.052399.
［43］WONG K K，ZARZHEVSKY N，CAHILL J M，et al．Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma［J］．AJR Am J Roentgenol，2008，191（6）：1785-1794．DOI：10.2214/AJR.08.1218.

[1]	CHENG Yu, YANG Rong, LONG Ren, LIAO Xiaoyang, ZHAO Yang. Study Design, Implementation and Case Analysis of Randomized Controlled Trials in Community-based Primary Care Settings [J]. Chinese General Practice, 2026, 29(31): 4528-4535.
[2]	LIU Danyi, SU Chonghong, YU Yaqi, ZHANG Haihao, LUO Hongchi, LUO Tianxiang, WANG Chen, WANG Hui, MA Hanying, ZHAO Tiefu. Reliability and Validity Analysis of the Chinese Localized Version of EUROPEP in Primary Healthcare Institutions in Beijing [J]. Chinese General Practice, 2026, 29(31): 4551-4558.
[3]	DENG Wei, HUANG Mengting, YI Shengli, LIN Yang, XU Lidan, REN Zhexue, ZHU Xiuqiong, LI Yesha, REN Mengge, KE Dazhi, LI Guiqiong, WU Zhiqin, LUO Aoran, HE Fapei. Training and Effectiveness of AI-enabled Clinical Reasoning in General Practice [J]. Chinese General Practice, 2026, 29(28): 4078-4085.
[4]	LI Yahui, XIE Kun, LIAN Lu, ZHANG Huaiping, CHEN Jiaying. Analysis of the Current Status of Professional Competence of Primary Care Doctors in China Based on the Iceberg Model [J]. Chinese General Practice, 2026, 29(27): 3891-3898.
[5]	HE Guoshu, REN Jingjing, ZHU Jiahong, MA Fanghui, SUN Wenping, LIU Lei, YIN Ankang, TANG Wenjuan. A Comparative Study of the Regional Characteristics of General Medically Unspecified Disease Patients in Northern and Southern China Based on Multi-center Real-world Data [J]. Chinese General Practice, 2026, 29(26): 3745-3751.
[6]	ZHAO Yawen, WANG Jieping, DU Xueping, WU Wei, YAN Wei, ZHOU Xiaoxia, GUAN Yajie, LI Qian, LI Haodong. Analysis of Disease Characteristics of Outpatients in the Department of General Practice at a Tertiary General Hospital in Beijing [J]. Chinese General Practice, 2026, 29(26): 3733-3738.
[7]	ZHAO Zezhou, WANG Jieping, DU Xueping, YAN Wei, WU Wei, LI Qian, ZHAO Yawen, LI Haodong. Analysis of Disease Characteristics of Inpatients in the Department of General Practice at a Tertiary General Hospital in Beijing [J]. Chinese General Practice, 2026, 29(26): 3739-3744.
[8]	YANG Xin, WANG Hong, XU Haofeng, HAN Jianjun, LIANG Wannian, HU Bingjie. Enlightenment of the Evolution Logic and Core Features of General Practice Definitions Abroad for the Development of General Practice in China [J]. Chinese General Practice, 2026, 29(25): 3553-3562.
[9]	YUAN Chengju, XIAO Xue, FAN Tengyang, LIU Shifang, HUANG Nian, ZHANG Nian, YU Changyin. Preliminary Construction of the Index System of Continuing Medical Education for Rural Order-oriented General Practitioners [J]. Chinese General Practice, 2026, 29(22): 3110-3115.
[10]	WANG Yang, ZOU Chuan, GUO Mengruo, HE Liuhua, LU Xuhang, GUI Xianzhong, XU Zhijie, LIN Kai, JIN Hua, YAO Mi, YANG Hui, YU Dehua. A Five-stage Approach for Primary Care Practitioners to Refine High-quality Research Questions with Artificial Intelligence Assistance [J]. Chinese General Practice, 2026, 29(22): 3094-3102.
[11]	ZHANG Zhenglu, WU Yihan. International Experience in the Development of Mental Health Special Interest in General Practice and Its Implications for China [J]. Chinese General Practice, 2026, 29(20): 2775-2780.
[12]	AN Xian, HUANG Peng, REN Jingjing. Investigation on the Cognition and Current Status of General Practitioners in the Multidisciplinary Diagnosis and Treatment of Medically Unexplained Symptoms [J]. Chinese General Practice, 2026, 29(18): 2472-2481.
[13]	FAN Meixiang, YAN Yunyun, HUANG Yanyan. Interpretation and Discussion of Guidelines for Preventive Activities in General Practice: Bladder Cancer [J]. Chinese General Practice, 2026, 29(18): 2450-2453.
[14]	WANG Yang, JIN Hua, YANG Sen, YANG Hui, YU Dehua. Reconfiguring the Functional Features of Primary Care in a Non-gatekeeping Context: a 15-Year Mixed-methods Systematic Review from China [J]. Chinese General Practice, 2026, 29(16): 2140-2155.
[15]	ZHANG Hanyu, GU Jie, LIN Yingnan, HUANG Yanyan. Discussion on the Application of AI-based Simulated-scenario Standardized Patients in the Standardized Training Teaching of General Practice Resident Physicians [J]. Chinese General Practice, 2026, 29(13): 1726-1731.